Viratek Inc. The drug research and development...

Viratek Inc. The drug research and development subsidiary of ICN Pharmaceuticals Inc. reported net income of $1.3 million for its 1990 fiscal year ended Nov. 30, contrasted with a loss of $17.1 million the previous year. Benefiting from royalties on increased sales of its antiviral drug, Virazole, the Costa Mesa company reported revenue of $4.9 million last year, up from $2.6 million in 1989. In the last three months of fiscal 1990, the company posted net income of $2.6 million on revenue of $4.4 million, contrasted with a net loss of $10.3 million on revenue of $1.7 million for the last quarter of fiscal 1989.